Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)

#483

Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.

Aim(s): To evaluate the time to first symptomatic recurrence (TSR) after Everolimus initiation in patients with RHMI.

Materials and methods: Patients with RHMI and treated with Everolimus between 2007 and 2011 were analysed in a restrospective multicentric study within the French group of endocrine tumors. Ongoing hyperglycemic medical options and safety were recorded.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bernard V, Lombard-Bohas C, Goichot B, Rohmer V, Guimbaud R,

Keywords: pancreatic endocrine tumor, insulinoma, Everolimus, hypoglycemia,